

Product Data Sheet

Product Name: PKM2-IN-6

Cat. No.: GC73767

Chemical Properties

Cas. No. 771467-00-6


Formula $C_{17}H_{14}N_4OS$ M.Wt 322.38

Solubility DMSO : 125 mg/mL (387.74 mM; Storage -20°C
Need ultrasonic)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

PKM2-IN-6 (compound 7d) is a potent and orally active PKM2 inhibitor with an IC₅₀ value of 23 nM. PKM2-IN-6 induces apoptosis and cell cycle arrest at G2 phase. PKM2-IN-6 reduces the level of PKM1 and PKM2 at the mRNA level. PKM2-IN-6 shows anticancer activity and has the potential for the research of triple-negative breast cancer.

PKM2-IN-6 (compound 7d) (0, 20, 40, 60, 80, 100 µM; 48 h) shows cytotoxicity with IC₅₀s of 18.33, 47.00, 19.80 µM for COLO-205, A-549, MCF-7 cells, respectively[1]. PKM2-IN-6 (14.38 µM; 48 h) induces apoptosis and cell cycle arrest at G2 phase[1]. PKM2-IN-6 (14.38 µM; 24 h) reduces the PKM1 and PKM2 at the mRNA level[1].

PKM2-IN-6 (25, 50 mg/kg; p.o.; daily for 3 weeks) decreases the tumor volume and tumor weight in mice[1].

References:

[1]. Das R, et al. Mechanistic Investigation of Thiazole-Based Pyruvate Kinase M2 Inhibitor Causing Tumor Regression in Triple-Negative Breast Cancer. J Med Chem. 2024 Feb 26.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA